Skip to content

Normal PSA by age

The age chart, why the limit changes over the years and what a first PSA says about the future.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 17, 2026
Book a consultation
Drawing of the prostate seen from above next to four bars rising from left to right, like PSA tends to rise with age, each topped with a PSA molecule
On this page

Quick answer

There is no single normal PSA value for every man. PSA rises with age as the prostate grows, and a 1993 study proposed age-specific limits: up to 2.5 ng/mL at 40 to 49, up to 3.5 at 50 to 59, up to 4.5 at 60 to 69 and up to 6.5 at 70 to 79.2 The European guideline notes that no limit is universally accepted and that, in screening, the most common cutoff is 3.0 ng/mL.1 In my practice, every result is assessed case by case, and an abnormal PSA takes me straight to an MRI.

Why the limit changes with age

PSA is a protein made by the prostate and measured in the blood. It is specific to the prostate, not to cancer, and it also rises with an enlarged prostate and with prostatitis.1

In most men the prostate grows over the years, and more tissue makes more PSA. In a study of 471 healthy men aged 40 to 79 with no sign of cancer, PSA rose with age and, even more closely, with prostate volume. At 60, the value went up by about 3.2% a year on average.2

That is where the idea of an age-adjusted limit came from. Because PSA rises over time in men without cancer, a consensus formed that the level considered high should rise too, as the American guideline notes.3 The same number, say 3.8 ng/mL, sits inside the range for a man in his 70s and above the range for a man in his 40s.2

PSA by age chart

The most quoted values come from an American study published in 1993. The limit for each group is the level below which 95% of healthy men of that age fell.2

AgePSA up to
40 to 492.5 ng/mL
50 to 593.5 ng/mL
60 to 694.5 ng/mL
70 to 796.5 ng/mL

Source: Oesterling and colleagues, JAMA, 1993.2 The chart helps you read the number, but it cannot tell whether cancer is present, and each result is assessed case by case. Finasteride and dutasteride lower PSA by about 50%, so the value has to be adjusted.1 I explain this in PSA and finasteride, and the other things that shift the test are in what affects PSA.

The drawbacks of age-specific ranges

A single cutoff, like the 4.0 ng/mL used for many years, misses in both directions. In a young man with a small prostate, it lets through a PSA that is already high for his age, and the diagnosis may be delayed. In an older man with a large prostate, it leads to more biopsies for benign growth.2,4 Age-specific ranges fix part of this, at a cost.

A study of 6,630 men aged 50 or older worked out the trade-off. Between 50 and 59, lowering the cutoff from 4.0 to 3.5 ng/mL would have raised the number of biopsies by 45% and, by projection, the cancers found by 15%. From 70 on, raising the cutoff to 6.5 ng/mL would have cut biopsies by 44% but missed 47% of cancers still confined to the prostate.4 The authors concluded that 4.0 should remain the cutoff at all ages.

No value gives complete reassurance either. In a large American study, men aged 62 to 91 whose PSA had never been above 4.0 ng/mL and whose rectal exam had never been abnormal had a biopsy after seven years. Cancer was found in 15.2% of them, and 14.9% of those tumors were Gleason 7 or higher. The rate was 6.6% with a PSA up to 0.5 ng/mL and 26.9% between 3.1 and 4.0 ng/mL.5 Some of these tumors would never have caused harm. Even so, the study shows that PSA works as a continuous scale, with no exact point separating normal from abnormal.1,5

What the guidelines say

According to the European guideline, there is no agreed standard for defining an abnormal PSA. In screening, the most common cutoff is 3.0 ng/mL or more, and with it 16.5% of invited men had a positive result.1 After a confirmed abnormal PSA, it recommends a prostate MRI, or another risk tool, to decide on a biopsy.1

The American guideline explains where the numbers came from. The 4 ng/mL cutoff came from early studies that looked at the highest values in men thought to be free of cancer. The 3 ng/mL cutoff came from the European screening trial, which lowered prostate cancer deaths using that threshold. The age-specific ranges, from 2.5 to 6.5 ng/mL, appear as the values most often cited in the literature.3

What to do after the result is in PSA: when to investigate, and the starting age each organization recommends is in screening.

Baseline PSA at 40 and 50

In the city of Malmö, Sweden, more than 21,000 men gave blood samples in the 1970s and 1980s for a heart study. Almost none of them had PSA tests in the years that followed. Decades later, researchers measured PSA in the stored blood and matched the results against who developed prostate cancer.

A single PSA taken between 44 and 50 predicted cancer diagnosed a median of 18 years later. The prediction held for men diagnosed 20 years or more after the blood draw, and each additional 1 ng/mL multiplied the odds of cancer by 3.7.6

In another analysis of the same cohort, 44% of prostate cancer deaths occurred in men who, at 45 to 49, were among the 10% with the highest PSA, 1.6 ng/mL or more. Below the median for that age, 0.68 ng/mL, the 15-year risk of metastasis was 0.09%.7 At 60, 90% of deaths occurred in men with a PSA above 2 ng/mL, and men at 1 ng/mL or less had a 0.2% risk of dying from the disease by 85.8

A study of American physicians, who had PSA tests more often than the Swedish men, found the same pattern between 40 and 59.9 The median is the value that splits men in half: half are below it.

AgeMedian PSA
40 to 490.68 ng/mL9
50 to 540.88 ng/mL9
55 to 590.96 ng/mL9
601 ng/mL8

Based on these data, the European guideline proposes follow-up tailored to the baseline PSA: tests every two years for men above 1 ng/mL at 40 or above 2 ng/mL at 60, and intervals of up to eight years for everyone else.1 The American guideline allows a baseline PSA between 45 and 50, and between 40 and 45 for men at higher risk, such as Black men, carriers of germline mutations or men with a strong family history.3 Cancer in this age group is covered in prostate cancer under 50.

How I approach it

I follow the guidelines, and the European one carries the most weight in my decisions. Even so, I recommend starting PSA testing at 40 for every man, because in real life I have seen many patients aged 40 to 45 with high-risk prostate cancer. There is more on this in when to start PSA testing.

Before the blood draw, I ask for at least 3 days of rest for the prostate: no ejaculation, no cycling and no rectal exam. When the PSA is normal, I repeat it once a year. The European guideline advises repeating the test after four weeks when the PSA is between 3 and 10 ng/mL and the rectal exam is normal.1 In my practice, when the PSA is abnormal, I go straight to a prostate MRI without repeating the PSA first.

I do not order free PSA routinely, or PSA density before the MRI. In my view, MRI has made these tests unnecessary, as I explain in free PSA and PSA density. I always look at the density after the MRI, calculated from the prostate volume: with PI-RADS 1 or 2, it is one of the parameters I use, but not the only one, and I weigh everything about the patient before deciding on a biopsy. With PI-RADS 3 or higher, I always recommend a biopsy, which I perform through the perineum and with sedation.

The European guideline considers that men without symptoms and with a life expectancy under 15 years are unlikely to benefit from early diagnosis.1 In my practice, I keep testing PSA as long as a man is healthy and has a life expectancy of more than 10 years.

When to see a urologist

  • From age 40, for your first PSA
  • If your PSA comes back abnormal or rises from one test to the next
  • If a first-degree relative has had prostate cancer, if you are Black or if you carry a BRCA2 mutation1
  • At any age, if you have urinary symptoms or blood in the urine

Frequently asked questions

What is a normal PSA for my age?

The most cited study suggests these limits: up to 2.5 ng/mL at 40 to 49, up to 3.5 at 50 to 59, up to 4.5 at 60 to 69 and up to 6.5 at 70 to 79.2 The European guideline points out that there is no limit everyone agrees on and that, in screening, the most common cutoff is 3.0 ng/mL.1 Each result is assessed case by case.

Why does PSA go up with age?

In most men the prostate grows over the years, and more tissue makes more PSA. In healthy men aged 40 to 79, PSA rose with age and, even more closely, with prostate volume.2

Does the 4.0 ng/mL cutoff apply at every age?

It was the standard cutoff for many years, and some studies argue for keeping it at all ages, because higher limits in older men missed part of the cancers.4 The American guideline notes a consensus that the limit should rise with age.3 The European guideline names 3.0 ng/mL as the cutoff most often used in screening.1

Does a PSA below the limit rule out cancer?

Not completely. In men aged 62 to 91 whose PSA had never gone above 4.0 ng/mL, biopsy found cancer in 15.2%, some of it higher grade.5 The lower the PSA, the lower the risk, but cancer is occasionally present even with a low PSA.1

At what age should I have my first PSA?

The European guideline advises starting at 50, at 45 with a family history or African ancestry, and at 40 with a BRCA2 mutation.1 The American guideline allows a baseline PSA between 45 and 50.3 In my practice, I recommend starting at 40 for every man, because I have seen many patients aged 40 to 45 with high-risk cancer.

What does a low PSA at 40 or 50 mean?

That the risk of a serious cancer in the following decades is low. In the Swedish Malmö cohort, men aged 45 to 49 with a PSA below 0.68 ng/mL had a 0.09% risk of metastasis over 15 years.7 The 10% with the highest PSA at that age, 1.6 ng/mL or more, accounted for 44% of deaths from the disease.7

How often should I repeat the PSA?

The European guideline suggests intervals based on the baseline PSA, every two years for men above 1 ng/mL at 40 or above 2 ng/mL at 60, and up to eight years for everyone else.1 In my practice, when the PSA is normal, I repeat it once a year.

Who can review my PSA in São Paulo?

I review PSA results for men of all ages in São Paulo, including a first test at 40. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. When the PSA is abnormal, my next step is a prostate MRI. My office is in Vila Mariana, and the first consultation can be in person or online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. EAU
  2. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860-864. PubMed
  3. Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023;210(1):46-53. PubMed
  4. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152(6 Pt 1):2037-2042. PubMed
  5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246. PubMed
  6. Lilja H, Ulmert D, Björk T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25(4):431-436. PubMed
  7. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023. PubMed
  8. Vickers AJ, Cronin AM, Björk T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521. PubMed
  9. Preston MA, Batista JL, Wilson KM, et al. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol. 2016;34(23):2705-2711. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation

Related guides